Cargando…

A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes

BACKGROUND: We investigated the effects of vildagliptin or alogliptin on blood glucose and hemoglobin A1c (HbA1c) in patients with type 2 diabetes inadequately controlled by sitagliptin. METHODS: In a single-center open-label trial, 35 patients with inadequate glycemic control on sitagliptin therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shigematsu, Erina, Yamakawa, Tadashi, Oba, Mari S., Suzuki, Jun, Nagakura, Jo, Kadonosono, Kazuaki, Terauchi, Yasuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458653/ https://www.ncbi.nlm.nih.gov/pubmed/28611856 http://dx.doi.org/10.14740/jocmr3012w

Ejemplares similares

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014)

Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping Syndrome
por: Amagai, Mari, et al.
Publicado: (2017)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Association of usual sleep quality and glycemic control in type 2 diabetes in Japanese: A cross sectional study. Sleep and Food Registry in Kanagawa (SOREKA)
por: Sakamoto, Rika, et al.
Publicado: (2018)

Spectrophotometric Methods for the Determination of Sitagliptin and Vildagliptin in Bulk and Dosage Forms
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

A new strategy for the determination of the antidiabetics alogliptin, saxagliptin and vildagliptin using all-solid state potentiometric sensors
por: Derar, Abeer Rashad, et al.
Publicado: (2023)

Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Chiba, Yukari, et al.
Publicado: (2018)

Dietary survey in Japanese patients with type 2 diabetes and the influence of dietary carbohydrate on glycated hemoglobin: The Sleep and Food Registry in Kanagawa study
por: Yamakawa, Tadashi, et al.
Publicado: (2018)

Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial
por: Zhou, Xiao-jun, et al.
Publicado: (2019)

Sleep duration and food intake in people with type 2 diabetes mellitus and factors affecting confectionery intake
por: Akiyama, Tomoaki, et al.
Publicado: (2023)

Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study
por: Takeshita, Yumie, et al.
Publicado: (2015)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
por: Kothny, Wolfgang, et al.
Publicado: (2015)

Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes
por: Yamazaki, Shunsuke, et al.
Publicado: (2022)

Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro
por: Shigematsu, Nao, et al.
Publicado: (2020)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Intra-retinal Arterial Cannulation using a Microneedle for Central Retinal Artery Occlusion
por: Kadonosono, Kazuaki, et al.
Publicado: (2018)

Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
por: Kaku, Kohei, et al.
Publicado: (2019)

Recurrent Subacute Thyroiditis in a Patient With Human Leukocyte Antigen–associated Predisposition to Graves Disease
por: Yamakawa, Tadashi, et al.
Publicado: (2021)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Effect of Switching From an Anti-Diabetic Loose Dose Combination to a Fixed Dose Combination Regimen at Equivalent Dosage for 6 Months on Glycemic Control in Japanese Patients With Type 2 Diabetes: A Pilot Study
por: Aoki, Kazutaka, et al.
Publicado: (2017)

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
por: Sakamoto, Masaya, et al.
Publicado: (2012)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
por: Kim, Hae Jin, et al.
Publicado: (2022)

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Associations of impaired glucose tolerance and sleep disorders with mortality among the US general population
por: Inoue, Kosuke, et al.
Publicado: (2021)

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
por: Li, Chun-Jun, et al.
Publicado: (2014)

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent
por: Tang, Yun-Zhao, et al.
Publicado: (2015)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
por: Sayari, Saba, et al.
Publicado: (2018)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients
por: Kurozumi, Akira, et al.
Publicado: (2017)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Liquid Chromatographic Determination of Alogliptin in Bulk and in its Pharmaceutical Preparation
por: El-Bagary, Ramzia I., et al.
Publicado: (2012)

Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin
por: Yin, Hao, et al.
Publicado: (2013)

Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis
por: Shima, Hisato, et al.
Publicado: (2019)

Necrotizing Pancreatitis Secondary to Hydrochlorothiazide and Alogliptin: A Case Report
por: Del Rio, Teresa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aiq2h2oo54u5h0cii882hcg6fj